| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:SEC inhibitor KL-2
CAS:900308-51-2
Purity:98% Package:5mg Remarks:S89687
|
SEC inhibitor KL-2 manufacturers
- SEC inhibitor KL-2
-
- $32.00 / 1mg
-
2025-06-12
- CAS:900308-51-2
- Min. Order:
- Purity: 98.03%
- Supply Ability: 10g
|
| | SEC inhibitor KL-2 Basic information |
| Product Name: | SEC inhibitor KL-2 | | Synonyms: | KL2;KL-2;KL 2;2-Butenamide, N-(5-chloro-2-methylphenyl)-4-(4-fluorophenyl)-2-hydroxy-4-oxo-;N-(5-Chloro-2-methylphenyl)-4-(4-fluorophenyl)-2-hydroxy-4-oxobut-2-enamide;SEC inhibitor KL-2, 10 mM in DMSO | | CAS: | 900308-51-2 | | MF: | C17H13ClFNO3 | | MW: | 333.74 | | EINECS: | | | Product Categories: | | | Mol File: | 900308-51-2.mol |  |
| | SEC inhibitor KL-2 Chemical Properties |
| Boiling point | 521.1±50.0 °C(Predicted) | | density | 1.400±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 8.09±0.50(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | SEC inhibitor KL-2 Usage And Synthesis |
| Uses | SEC inhibitor KL-2 (KL-2), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-2 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 1.50 μM[1]. | | Biochem/physiol Actions | Disruptor of SEC (super elongation complex) | | in vivo | SEC inhibitor KL-2 (10 mg/kg, i.p., once daily for 15 days) delays tumor growth and prolonged survival in the MDA231-LM2 xenograft tumor model in nude mice[1]. | Animal Model: | MDA231-LM2 xenograft tumor model in nude mice[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), once daily for 15 days | | Result: | Significantly delayed tumor growth and increased survival of mice. |
| | References | [1] Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779. DOI:10.1016/j.cell.2018.09.027 |
| | SEC inhibitor KL-2 Preparation Products And Raw materials |
|